



COMPANY OVERVIEW

Amarantus BioScience Holdings, Inc. is a publicly traded biotechnology company focused on developing therapeutic products with the potential for orphan drug designation in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, and diagnostics in neurology.

RECENT NEWS

Todos Medical Raises \$1,350,500 In Funding and Finalizes Joint Venture Agreement with Amarantus Bioscience

Feb 28 2019, 9:30 AM EST

MANF Therapeutics Receives Notices of Allowance Covering MANF Use as Treatment for Parkinson's in Europe and Diabetes in Japan

Jan 17 2019, 7:00 AM EST

MANF Therapeutics Receives Notice of Allowance from US Patent & Trademark Office Covering the Use of MANF or CDFN as a Treatment for Glaucoma, Macular Degeneration and Retinitis Pigmentosa

Jan 15 2019, 7:00 AM EST

STOCK OVERVIEW

Symbol	AMBS
Exchange	OTCPink
Shares OS	68,272,000
Market Cap	\$1.71M
Last Price	\$0.0251
52-Week Range	\$0.0151 - \$0.0765
Fiscal Year End	December 31

05/17/2019 02:34 PM EDT

INVESTOR RELATIONS

American Capital Ventures, Inc.
Howard Gostfrand
President
T: 305-918-7000
F: 305-468-6165
hg@amcapventures.com

MANAGEMENT TEAM

Gerald E. Commissiong
President & Chief Executive Officer

Brian E. Harvey, MD, PhD
Chief Regulatory Advisor

Elise Brownell, Ph.D.
Senior Vice President of Operations and Project Management

John W. Commissiong, PhD
Chief Scientific Officer

Paula Trzepakz, MD
Chief Medical Advisor to Elto Pharma

Dr. Richard Kagan
Chief Medical Advisor to Cutanogen Corporation

Michael T. Ropacki, PhD
Chief Medical Advisor - Alzheimer's Blood Diagnostic LymPro Test®

AMARANTUS BIOSCIENCE HOLDINGS, INC.

45 Wall Street
Suite 920
New York, NY 10005
US

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.